التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
التداول ينطوي على مخاطر
الاستثمارات تنطوي على مخاطر وليست مناسبة لجميع المستثمرين. العقود مقابل الفروقات هي أدوات معقدة وتنطوي على مخاطر عالية لخسارة الأموال بسرعة بسبب الرافعة المالية.
Gilead Sciences Inc.
Open
Sector Healthcare
89.43 0.86
Overview
Share price change
24h
Min
87.91
Max
89.43
Income | -361M 1.3B |
|---|---|
Sales | 540M 7.5B |
P/E Sector Avg | 190.58 94.998 |
EPS | 2.02 |
Dividend yield | 3.674 |
Profit margin | 16.618 |
Employees | 18,000 |
EBITDA | 780M 3.8B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +11.64 upside |
Dividend yield Sector Avg | 3.67% 2.40% |
|---|---|
Next Earnings | ٤ فبراير ٢٠٢٥ |
Next Dividend date | ٣٠ ديسمبر ٢٠٢٤ |
Next Ex Dividend date | ١٣ ديسمبر ٢٠٢٤ |
Market Cap | 1.1B 113B |
|---|---|
Previous open | 88.57 |
Previous close | 89.43 |
News Sentiment
By Acuity
16%
84%
32 / 392 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Gilead Sciences Inc. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Gilead Sciences Inc. Forecast
Price Target
By TipRanks
11.64% upside
12 Months Forecast
Average 98.95 USD 11.64%
High 125 USD
Low 80 USD
Based on 23 Wall Street analysts offering 12 month price targets forGilead Sciences Inc. - Dist in the last 3 months.
Sentiment
By Acuity
32 / 392 Ranking in Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Gilead Sciences Inc.
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
